I-Mab at Jefferies London Healthcare Conference TranscriptNov 14, 2023- Half Year 2023 I-Mab Earnings Call TranscriptAug 17, 2023$2.3 (-2.95%)Earnings
- Full Year 2022 I-Mab Earnings Call TranscriptMar 31, 2023$3.46 (-1.70%)Earnings
- I-Mab Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab Call TranscriptSep 12, 2022
- Half Year 2022 I-Mab Earnings Call TranscriptAug 30, 2022$5.98 (+2.57%)Earnings
- I-Mab R&D Day TranscriptJul 20, 2022
- I-Mab TJD5 Phase 2 Clinical Trial Data Update Call TranscriptMay 27, 2022
- Full Year 2021 I-Mab Earnings Call TranscriptMar 29, 2022$19.39 (+15.07%)Earnings
- I-Mab at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- I-Mab Corporate Call TranscriptDec 21, 2021
- I-Mab Most Recent Clinical Data Update Conference Call -- English Session TranscriptDec 14, 2021
- I-Mab and Jumpcan To Announce its Strategic Commercial Partnership on Eftansomatropin Alfa - Special Call TranscriptNov 10, 2021
- Half Year 2021 I-Mab Earnings & Corporate Progress Update Conference Call TranscriptAug 31, 2021
- I-Mab to Discuss Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 Call TranscriptJun 07, 2021
- I-Mab at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- I-Mab Corporate Analyst Meeting TranscriptApr 26, 2021
- Full Year 2020 I-Mab Earnings Call TranscriptMar 29, 2021$44.38 (-4.80%)Earnings
- IMAB Lemzoparlimab Phase 1 Clinical Trial Data Update Conference Call TranscriptNov 13, 2020
- I-Mab SITC Data Conference Call TranscriptNov 09, 2020
- I-Mab Company Update Conference Call TranscriptSep 04, 2020
- Half Year 2020 I-Mab Earnings Call TranscriptAug 31, 2020$39.44 (+27.23%)Earnings
- I-Mab Update Conference Call TranscriptMay 28, 2020
- I-Mab at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Full Year 2019 I-Mab Earnings Call TranscriptMar 31, 2020$13 (+4.00%)Earnings
I-Mab at Jefferies London Healthcare Conference Transcript
Okay. Shall we start? Okay, great. Good morning, everyone. Thank you for attending Jefferies London Healthcare Conference. My name is Kelly Shi, one of the biotech analysts here. Please join me and welcome Mr. Raj Kannan, CEO, and Dr. John Hayslip, CMO of I-Mab Biopharma for this fireside chat session. Welcome both.
Questions & Answers
Maybe to start off, can you talk about for the past several months, after you got on board, Raj, what has been your focus, what has kept you busy? And what is your plan for the next 12 months?
So first and foremost, Kelly, thank you for giving us the opportunity to present our investment thesis at this investment conference.
I think I've been onboard for four months right now. And the first and foremost was the science, really, to look at the portfolio. And so there's been a lot of work within the company to be able to focus on what's the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
